PD-L1 >= 1%
About
Biomarker Type: Protein expression
Present: True
Marker: PD-L1
Unit: Tumor Proportion Score (TPS)
Equality: >=
Value: 0.01
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Atezolizumab | |
| FDA (1) HC (2) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Ipilimumab, Nivolumab | |
| FDA (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Ipilimumab, Nivolumab | |
| FDA (1) HC (1) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Pembrolizumab | |
| FDA (1) HC (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Pembrolizumab | |
| HC (2) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Ipilimumab, Nivolumab | |
| HC (1) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Nivolumab | |
| HC (1) | ER negative, HER2-negative, PD-L1 >= 1%, PR negative | Invasive Breast Carcinoma | Atezolizumab, Nab-paclitaxel | |
| HC (1) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Fluorouracil, Nivolumab, Oxaliplatin |